Karuna Therapeutics Executive Compensation (FY22)
KRTX · Executive and director compensation, fiscal 2022 only
Chief executive, fiscal 2022 ◇ Steven Paul | Latest say-on-pay support = June 20, 2023 | Chief executive pay ratio ◇ To the median employee |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Karuna Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Data as of November 5, 2026Latest filing (8-K): June 21, 2023
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
119 figures on this page: 117 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
More on Karuna Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Karuna Therapeutics' chief executive and what were they paid?
Steven Paul, President and Chief Executive Officer, received $11,224,103 in total compensation for fiscal 2022.
What was Karuna Therapeutics' say-on-pay result?
For fiscal 2022, shareholders backed the say-on-pay proposal with 65.2% of votes cast for or against in favor at the meeting held June 20, 2023.
Which companies are in Karuna Therapeutics' peer group?
Companies named in the disclosed peer group include Acadia Pharmaceuticals Inc., Alector, Inc., Allakos Inc., Apellis Pharmaceuticals, Inc. and Arvinas, Inc., among others.
What is Karuna Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2022 is 27:1.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Steven Paul President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Andrew Miller Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Stephen Brannan Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Troy Ignelzi Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Charmaine Lykins Chief Commercial Officer | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Miller | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Stephen Brannan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Steven Paul | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Troy Ignelzi | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Steven Paul | Option | ◇ | — | ◇ | 2/15/2032 |
| Option | ◇ | — | ◇ | 2/22/2031 | |
| Option | ◇ | — | ◇ | 2/13/2030 | |
| Andrew Miller | Option | ◇ | — | ◇ | 2/15/2032 |
| Option | ◇ | — | ◇ | 2/22/2031 | |
| Option | ◇ | — | ◇ | 2/13/2030 | |
| Charmaine Lykins | Option | ◇ | — | ◇ | 11/28/2031 |
| Stephen Brannan | Option | ◇ | — | ◇ | 2/15/2032 |
| Option | ◇ | — | ◇ | 2/22/2031 | |
| Option | ◇ | — | ◇ | 2/13/2030 | |
| Option | ◇ | — | ◇ | 3/20/2029 | |
| Troy Ignelzi | Option | ◇ | — | ◇ | 2/15/2032 |
| Option | ◇ | — | ◇ | 3/21/2029 | |
| Option | ◇ | — | ◇ | 2/22/2031 | |
| Option | ◇ | — | ◇ | 2/13/2030 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Andrew Miller
Chief Operating Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Charmaine Lykins
Chief Commercial Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Stephen Brannan
Chief Medical Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Steven Paul
President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Troy Ignelzi
Chief Financial Officer · Employment agreement
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Christopher J. Coughlin Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Laurie Olson | ◇ | — | ◇ | — | — | — | ◇ |
Atul Pande, M.D | ◇ | — | ◇ | — | — | — | ◇ |
James Healy, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Denice Torres | ◇ | — | ◇ | — | — | — | ◇ |
David Wheadon, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey Jonas, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Steven Paul, M.D and Bill Meury served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Acadia Pharmaceuticals Inc. ACAD
- Alector, Inc. ALEC
- Allakos Inc. ALLK
- Apellis Pharmaceuticals, Inc. APLS
- Arvinas, Inc. ARVN
- Axsome Therapeutics, Inc. AXSM
- Biohaven Pharmaceutical Holding Company Ltd. BHVN
- BioXcel Therapeutics, Inc. BTAI
- Cerevel Therapeutics Holdings, Inc. CERE
- Cortexyme, Inc. symbol not shown
- Denali Therapeutics Inc. DNLI
- Intra-Cellular Therapies, Inc. ITCI
- Kodiak Sciences Inc. KOD
- Mirati Therapeutics, Inc. MRTX
- Prothena Corporation plc PRTA
- Rhythm Pharmaceuticals, Inc. RYTM
- Sage Therapeutics, Inc. SAGE
- TG Therapeutics, Inc. TGTX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2022 | June 20, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 15, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Steven Paul (President and Chief Executive Officer), FY2022 total compensation $11,224,103 (base salary $700,000) [exec_comp, SEC accession 0000950170-23-014979, filed 2023-04-27]What this page does not include
Everything above is a fact Karuna Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Karuna Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Karuna Therapeutics recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
119 figures on this page: 117 cited to the filing that reported them, 2 calculated from figures it prints.
117 cited to the filing
2 calculated from the filing
Documents cited
- 0000950170-23-029140Proposal 2 – Advisory vote on the compensation paid to the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.
- 0000950170-23-014979CEO Pay Ratio Disclosure · Director Compensation in 2022 · Grants of Plan-Based Awards for Fiscal Year 2022 · Potential Payments upon Termination
- 0001193125-22-177034Proposal 2 – Advisory vote on the compensation paid to the Company’s named executive officers The Company’s stockholder’s approved, on an advisory basis, the compensation paid to the Company’s named executive officers.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Karuna Therapeutics executive compensation, FY2022.” https://intel.velarion.ai/comp/KRTX (accessed 2026).
Short form: data: Velarion
The paid brief for Karuna Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Karuna Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Karuna Therapeutics discloses
The companies named in KRTX's own disclosed peer group.
Acadia Pharmaceuticals Inc.Alector, Inc.Allakos Inc.Apellis Pharmaceuticals, Inc.Arvinas, Inc.Axsome Therapeutics, Inc.Biohaven Pharmaceutical Holding Company Ltd.Cerevel Therapeutics Holdings, Inc.Denali Therapeutics Inc.Intra-Cellular Therapies, Inc.Kodiak Sciences Inc.Mirati Therapeutics, Inc.Prothena Corporation plcRhythm Pharmaceuticals, Inc.Sage Therapeutics, Inc.TG Therapeutics, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}